Structure Therapeutics (NASDAQ:GPCR) Trading Down 8.5% – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s stock price dropped 8.5% during mid-day trading on Tuesday . The stock traded as low as $59.05 and last traded at $59.28. Approximately 485,488 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 1,054,659 shares. The stock had previously closed at $64.80.

Analyst Ratings Changes

A number of research firms have recently commented on GPCR. Zacks Research cut shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the company a “buy” rating in a research note on Thursday. Lifesci Capital upgraded Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Structure Therapeutics in a report on Friday, November 28th. Finally, Wall Street Zen raised Structure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $95.78.

Structure Therapeutics Trading Down 7.7%

The company has a market capitalization of $3.63 billion, a P/E ratio of -49.28 and a beta of -1.64. The stock’s 50-day moving average price is $36.25 and its 200-day moving average price is $26.13.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of large investors have recently modified their holdings of GPCR. National Bank of Canada FI lifted its position in Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after purchasing an additional 2,766 shares during the last quarter. Invesco Ltd. boosted its position in shares of Structure Therapeutics by 6.1% during the first quarter. Invesco Ltd. now owns 394,386 shares of the company’s stock worth $6,827,000 after buying an additional 22,619 shares during the period. Aberdeen Group plc raised its stake in Structure Therapeutics by 45.2% during the 1st quarter. Aberdeen Group plc now owns 248,899 shares of the company’s stock valued at $4,308,000 after acquiring an additional 77,511 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Structure Therapeutics in the first quarter worth $249,000. Finally, Capital Fund Management S.A. grew its stake in shares of Structure Therapeutics by 18.7% in the first quarter. Capital Fund Management S.A. now owns 79,656 shares of the company’s stock worth $1,379,000 after purchasing an additional 12,521 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.